Health Canada Approves MedMira’s Reveal G4 Rapid HIV Test for Point-of-Care

MedMira Inc. (MedMira) announced that it has received the approval from Health Canada for its Reveal Rapid G4 HIV-1/2 Test (Reveal HIV test) for Point-of-Care (POC) use. The Reveal HIV rapid test has achieved a sensitivity of 99.64% and a specificity of 99.71% and with it is highly suitable for health care professionals who require a fast, reliable, and high-quality result to be used in any health care setting.

The Reveal HIV test enables an immediate result to accurately detect HIV-1/2 antibodies with only a small sample using a finger prick. The less then 1-minute easy steps to complete the test (after sample collection), allows an operator to achieve an immediate result that does not fade away. This together with the no special storage requirement makes the Reveal HIV test a highly suitable tool for any health care setting.

The product is based on MedMira’s unique and patented Rapid Vertical Flow Technology with an in-build reagent and procedural control line which enables users to be sure the test is performed correctly. This distinctive feature provides the comfort and security that a test has been correctly completed. An essential part for any rapid testing, especially for life changing diagnoses such as HIV.

“Our Reveal HIV test is one of the fastest and most reliable solutions for HIV detection. As the rates of HIV infections continue to rise in Canada, healthcare providers need diagnostics that are not only accurate but also simple, cost-effective, and accessible in any setting. Whether in underserved remote areas or urban centres facing overburdened healthcare systems, our test is designed to provide immediate and actionable results. ,” said Hermes Chan, CEO of MedMira. “Together with our partners, such as REACH Nexus, we are committed to rapidly deploying our innovative solutions and supporting Canada’s public health efforts to modernize and expand HIV screening.”

The latest data from the Public Health Agency of Canada, shows that new HIV diagnoses soared more than 35% from 2022 to 2023, with rates in Manitoba rising by more than 40%. In Saskatchewan, the rate of HIV was 19.4 per 100,000 people, more than three times the national rate.

This approval comes after the received approval of MedMira’s Multiplo TP/HIV rapid test on the 24th of December 2024. The company’s aim is to provide the Canadian market with a suite of alternatives as certain health care settings and programmes or professionals aim for a specific disease. Hence the company offers its Multiplo TP/HIV combination test or its Reveal single marker tests such as Reveal HIV test. MedMira anticipates the approval of the Reveal TP test in the coming weeks.

MedMira is a leading developer and manufacturer of Rapid Vertical Flow diagnostics. The company’s tests provide hospitals, labs, clinics, and individuals with instant disease diagnosis, such as HIV, Syphilis, Hepatitis, and SARS-CoV-2, in just three easy steps.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!